Quick Answer
Xeris Biopharma Holdings, Inc. reported Diluted EPS of $0.00 per share for fiscal year 2025.
Xeris Biopharma Holdings, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.00 | +100.0% |
| 2024 | -$0.37 | +17.8% |
| 2023 | -$0.45 | +35.7% |
| 2022 | -$0.70 | +54.8% |
| 2021 | -$1.55 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | +100.0% | +100.0% |
| June 30, 2025 | -$0.01 | +90.0% | +83.3% |
| March 31, 2025 | -$0.06 | +57.1% | +45.5% |
| September 30, 2024 | -$0.11 | -22.2% | -10.0% |
| June 30, 2024 | -$0.10 | +28.6% | +28.6% |
| March 31, 2024 | -$0.14 | -16.7% | -55.6% |
| September 30, 2023 | -$0.09 | +43.8% | +35.7% |
| June 30, 2023 | -$0.14 | +26.3% | -16.7% |
- Xeris Biopharma Holdings, Inc. showed an increase of +100.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Xeris Biopharma Holdings, Inc.’s diluted eps has grown by 100.0% (from $1.55 per share (loss) to $0.00 per share).
- The most recent figure is from Xeris Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: